CBMX
CombiMatrix Corporation
Set alert
- Open
- 6.55
- Prev close
- 6.25
- Mkt cap
- 18.40M
- Vol
- 51.82K
- Avg vol
- 42.87K
- EPS
- -0.877
- P/E
- -7.13
- Div yield
- 0.00%
More statistics
- Low
- 6.11
- High
- 6.60
- Forward P/E
- 208.33
- Beta
- 1.65
- Short ratio
- 2.74
- Inst. own
- 28.17%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 30, 2019
- 50-d avg
- 6.32
- 200-d avg
- 6.82
- 1y target
- 7.73
Key statistics
- Market cap
- 18.40M
- Enterprise value
- 17.68M
- Trailing P/E
- -7.13
- Forward P/E
- 208.33
- PEG ratio
- 0.00
- Price / sales
- 1.24
- Price / book
- 3.07
- EPS (TTM)
- -0.877
- Beta
- 1.65
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- -15.53%
- Revenue (TTM)
- 14.82M
- Revenue growth
- 36.50%
- Free cash flow
- -1.12M
- Total cash
- 3.02M
- Total debt
- 121.00K
- Return on equity
- -33.95%
- Shares outstanding
- 2.94M
- Short % of float
- 7.30%
- 50-day average
- 6.32
- 200-day average
- 6.82
Analyst view
Consensus: buy
- Target (low)
- 7.70
- Target (mean)
- 7.73
- Target (high)
- 7.77
Next earnings
Nov 30, 2019
Expected Nov 30, 2019. Consensus EPS estimate -0.13.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 30, 2019 | Jun 1, 2010 | 0.00 | — | — | — |
| Nov 6, 2017 | Sep 1, 2017 | -0.12 | — | — | — |
| Aug 3, 2017 | Jun 1, 2017 | -0.17 | — | — | — |
| May 4, 2017 | Mar 1, 2017 | -0.28 | — | — | — |
| Feb 22, 2017 | Dec 1, 2016 | -0.41 | — | — | — |
| Nov 2, 2016 | Sep 1, 2016 | -1.07 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 3, 2017 | Ladenburg Thalmann | down | Buy | Neutral |
| Jul 12, 2017 | Aegis Capital | init | — | Buy |
| Oct 5, 2016 | Aegis Capital | init | — | Buy |
About CombiMatrix Corporation
CombiMatrix Corporation provides clinical molecular diagnostic laboratory services in the United States. The company focuses on pre-implantation genetic screening, prenatal diagnosis, miscarriage analysis, and pediatric developmental disorders. It provides molecular diagnostic services primarily in the areas of reproductive health for the diagnosis of developmental disorders associated with intellectual disability, congenital anomalies, dysmorphic features, and autism spectrum disorders. The companys testing focuses on advanced technologies, including single nucleotide polymorphism, chromosomal microarray analysis, sequencing, fluorescent in situ hybridization, and high resolution karyotyping. It serves commercial insurance companies, healthcare institutions, government payors, and individuals. CombiMatrix Corporation was founded in 1995 and is headquartered in Irvine, California.
- Sector
- Healthcare
- Industry
- Medical Laboratories & Research
- Country
- United States
- Website
- combimatrix.com
News
No recent headlines
Headlines appear here as they are published.
Your note
Sign in to keep a note on CBMX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BURELL SCOTT R | Officer | Disposition (Non Open Market) | Nov 13, 2017 | 0 |
| GOTTLIEB SCOTT | Director | Purchase | May 8, 2016 | 4,804 |
| HOFFMAN ROBERT | Director | Disposition (Non Open Market) | Nov 13, 2017 | 0 |
| JESSUP R JUDD | Director | Disposition (Non Open Market) | Nov 13, 2017 | 0 |
| JONES JEREMY M | Director | Disposition (Non Open Market) | Nov 13, 2017 | 0 |
| MCDONOUGH MARK D | Officer | Disposition (Non Open Market) | Nov 13, 2017 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Acuta Capital Partners LLC | 3.80% | 111,912 | 839.34K | Sep 29, 2017 |
| Renaissance Technologies, LLC | 3.37% | 99,100 | 743.25K | Sep 29, 2017 |
| Bard Associates Inc. | 2.76% | 81,281 | 609.61K | Sep 29, 2017 |
| Deutsche Bank Aktiengesellschaft | 2.58% | 75,901 | 569.26K | Sep 29, 2017 |
| Essex Investment Management Co Inc | 2.24% | 66,070 | 495.52K | Sep 29, 2017 |
| Stonepine Capital Management, LLC | 2.15% | 63,283 | 474.62K | Sep 29, 2017 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Bridgeway Funds Inc-Ultra Small Company Fund | 1.35% | 39,800 | 210.94K | Jun 29, 2017 |
| Vanguard Extended Market Index Fund | 0.93% | 27,245 | 144.40K | Jun 29, 2017 |
| iShares Core S&P Total U.S. Stock Market ETF | 0.41% | 12,120 | 91.51K | Aug 30, 2017 |
| DFA U.S. Micro Cap Series | 0.24% | 7,020 | 33.34K | Apr 29, 2017 |
| DFA U.S. Targeted Value Portfolio | 0.18% | 5,427 | 25.78K | Apr 29, 2017 |
| DFA U.S. Small Cap Series | 0.16% | 4,610 | 21.90K | Apr 29, 2017 |